Renaissance Capital logo

Oyster Point Pharma Priced, Nasdaq: OYST

Phase 3 biotech developing a nasal spray formulation for dry eye disease.

Industry: Health Care

First Day Return: +17.4%

Industry: Health Care

We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Our lead product candidate OC-01 (varenicline), a highly selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease (DED). OC-01’s novel mechanism of action is designed to re-establish tear film homeostasis by activating the trigeminal parasympathetic pathway and stimulating the glands and cells responsible for natural tear film production. In our Phase 2b clinical trial (ONSET-1) in 182 subjects, OC-01 demonstrated statistically significant improvements (as compared to placebo) in both signs and symptoms of DED. Based on OC-01’s clinical trial results and its rapid onset of action, we believe OC-01, if approved, has the potential to become the new standard of care and redefine how DED is treated for millions of patients. We initiated a Phase 3 clinical trial (ONSET-2) in July 2019 and expect to report top-line results in mid-2020, with a potential New Drug Application (NDA) expected in the second half of 2020.
more less
IPO Data
IPO File Date 10/04/2019
Offer Price $16.00
Price Range $16.00 - $18.00
Offer Shares (mm) 5.0
Deal Size ($mm) $80
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 10/30/2019
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $80
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters Princeton, NJ, United States
Founded 2015
Employees at IPO 18
Website www.oysterpointrx.com

Oyster Point Pharma (OYST) Performance